EGFR and metastatic colorectal cancer: In the context of systemic chemotherapy for metastatic colorectal cancer (mCRC), new molecular targeted agents such as anti-vascular endothelial growth factor antibodies [1], anti-epidermal growth factor receptor (EGFR) antibodies [2, 3], and multi-tyrosine kinase inhibitors [4] were sequentially introduced.